PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP (EPAG)

Similar documents
The Role of EPAG in Standards and Regulatory Guidance Development

Last updated: July 2011

The abbreviated impactor measurement concept

EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010

Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)

The effect of different coating materials on the prevention of powder bounce in the next generation impactor

Caption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).

EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing. Overview of AIM EDA

INTRODUCTION. size and total nozzle area decrease with stage number. Volumetric air flow rate through

Understanding cascade impaction and its importance for inhaler testing

Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing

OVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA)

Inhalation Product Research at FDA

905 UNIFORMITY OF DOSAGE UNITS

Metered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC

DEBATING THE OPERATING CURVES FOR DDU TESTS ON MARKETED INHALERS

Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016

Assessing the role of breathing simulators in OIP testing

REFERENCES OVERVIEW ADVANTAGES AEROSOLS. Aerosols. and Foams

Testing Inhaled Generics

Go With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific

OF COATING MATERIAL ON THE AERODYNAMIC PARTICLE SIZE DISTRIBUTION (PSD) OF OXIS TURBOHALER USING MIXING INLET WITH AN ANDERSEN CASCADE IMPACTOR (ACI)

What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables

IVIVC in Pediatric OIPs

AEROSOL THERAPY: THE PRACTICALITIES

Formulation Considerations for Inhaled Products

Teerapol SRICHANA,*,a Anthony BRAIN, b Christopher MARRIOTT, c and Gary Peter MARTIN c

The Collapsible Chamber

Device Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015

International Pharmaceutical Aerosol Consortium on Regulation and Science

Device Design Similarity

University of Groningen. Technology in practice Lexmond, Anne

ADDITIONAL TECHNOLOGIES FOR PRESSURIZED METERED DOSE INHALERS. Steve Newman Scientific Consultant Nottingham, UK

SELECTION AND VALIDATION OF CASCADE IMPACTOR TEST METHODS

Metered Dose Inhaler Technology

Next Generation Pharmaceutical Impactor (A New Impactor for Pharmaceutical Inhaler Testing). Part I: Design ABSTRACT

Ingredient Listing Qty. Unit NDC # Supplier ml

Implications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING

COPLEY SCIENTIFIC. Quality Solutions for Inhaler Testing Edition. metered-dose inhalers dry powder inhalers nebulisers nasal sprays

Assessing Quality of Inhaled Products And Links to Efficacy and Safety

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

21 Virginiamycin OH O. For chickens (except for broilers) broilers. Added amount 5~15 5~15 10~20 10~20

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

ARTESUNATE TABLETS: Final text for revision of The International Pharmacopoeia (December 2009) ARTESUNATI COMPRESSI ARTESUNATE TABLETS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS

Smart asthma therapy. Patient information Spacer inhaling aid for metered-dose aerosol inhalers

Process Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations

COPLEY SCIENTIFIC. Quality Solutions for Inhaler Testing. metered-dose inhalers dry powder inhalers nebulisers nasal sprays

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PAEDIATRIC RETINOL ORAL SOLUTION (August 2010)

Product Guide. MSP Corporation Rice Creek Parkway, Suite 300. Shoreview, Minnesota 55126, U.S.A. Phone: Fax:

Metering Valve Design and Material Selection; How can this be chosen to maximize product performance?

Current Challenges and Opportunities in Demonstrating Bioequivalence

Quality of Nasal and Inhalation Drug Products

Ensuring the Quality of Some Drug-Device Combination Products - FDA Perspective

The Montreal Protocol and the Phase-out of CFC-based Metered Dose Inhalers. Paul Krajnik UNIDO, Montreal Protocol Branch

Respiratory Therapy. Medical/Scientific/General Background

1. Module Details PENETRANT TESTING. 2. Module Purpose To enable students to develop a detailed understanding of the

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

MDI. Recommended Equipment

Respiratory. Martin Jetzer DDL27 Edinburgh December 2016

REVISED DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA RETINOL CONCENTRATE, OILY FORM. (August 2010)

8/13/11. RSPT 1410 Humidity & Aerosol Therapy Part 3. Humidification Equipment. Aerosol Therapy

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

A NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

Drug/Device Combination Products: Bioequivalence

NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS

21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Cascade Impactor Study Comparing the Amsino OneMask Oxygen Mask and Predicate Mask from Hudson RCI on a Human Model

Preparation and Administration

Senior Scientist / Principal Scientist. Compounding Manager (Sterile and non-sterile specials) Senior Pharmaceutical Assessor

Understanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016

The Use of Physics-Based Modeling to Better Design Drug- Device Interface. Yoen-Ju Son, PhD Merck Research Laboratory, Summit, NJ

Varroa Mite Detection Methods

Formulation and Development of Metered Dose Inhalations of Salbutamol in Solution Form

Rebaudioside a From Multiple Gene Donors Expressed in Yarrowia Lipolytica

Issued by: LABORATORY MANAGER Original Date: March 20, 2000 Approved by: Laboratory Director Revision Date: July 26, 2000 CRYPTOCOCCAL ANTIGEN

EUDRAGIT L 100 and EUDRAGIT S 100

Metered Dose Inhalation Formulations of Salbutamol Sulphate Using Non-CFC Propellant Tetrafluoroethane

SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical

Hepatitis A virus IgM ELISA Kit

Misty Max 10 nebulizer

Study of the British Pharmacopeia method on methimazole (thiamazole) content in carbimazole tablets

The pulmonary route is gaining increasing

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

WHAT IS NSP? ( ANTIFINGERPRINTS NANOCOATING by The Inox in Color )

Sub-components in Nicotine cessation products?

VARIABILITY IN CASCADE IMPACTION: SOURCES, IMPACT AND STRATEGIES FOR REDUCTION

Emulsions. Purpose of emulsions and of emulsification:

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

Aerosol Delivery Devices

Mouse C-Peptide ELISA Kit

Transcription:

PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP () J.P. Mitchell on behalf of members of the European Pharmaceutical Aerosol Group Summary members evaluate many different aerosols from both pressurized metered dose inhalers (pmdis) and dry powder inhalers (s) by the use of a cascade impactor. It is widely recognized that pre-coating of particle collection surfaces is a prerequisite in testing to avoid bias caused by particle bounce. A summary of a recent survey is presented, in which members were asked to provide information about their impactor type and coating methodology, including the composition of the coating material applied to the collection surfaces. There is no standard approach in terms of either materials used or method of applying the coating. However, standardization is unnecessary, since each organization has independently selected and validated their procedure with their own formulations. The newcomer can therefore select from a variety of methods to eliminate particle bounce, and at the same time ensure quantitative recovery and assay of the active pharmaceutical ingredient(s). Introduction Coating of the collection surfaces of the cascade impactor with a media that provides a tacky surface is recognized as an appropriate precaution to minimize particle bounce and reentrainment, especially when testing dry powder inhalers (s) [1,2]. Studies with both the Andersen 8-stage impactor (ACI) [3] and Next Generation Pharmaceutical Impactor () [4] indicate that collection surface coating may also be required for some formulations delivered by pressurized metered dose inhaler (pmdi), especially when measurements are being made with a low number of actuations from the inhaler. The table summarizes the coating methods that are currently in use by members of. Impactor Collection Surface Coating Methods ACI Andersen 8-stage impactor, MMI Marple-Miller impactor, Next Generation Pharmaceutical impactor, VHC valved holding chamber

Table 1. Coating Methods Used by Organizations 1 ACI pmdi 2 ACI 3 ACI, 4 ACI pmdi & 5 ACI pmdi, or Aluminium alloy 6 ACI, 7 ACI, 8 ACI, pmdi, Ethanolic solution of Brij35 (polyoxyethylenelaurylether) is mixed with glycerol 11% polypropylene glycol in Hexane A solution of Brij, glycerol and ethanol (ethanol evaporates after applying, before analysis) Glycerol or Brij 35. Applied only if required 1 ml of Brij 35 in 20 ml ethanol dissolved in 5 g glycerol n-hexane + 1% of SPAN 85 (sorbitan trioleate) 1% w/v silicone oil in hexane Dip plate into coating solution, leave in a fume hood to allow solvent to evaporate before assembly of impactor Submerge plate, remove plate allowing the bulk to drain off, then air dry Apply standard amount of coating material (thin) evenly (in practise done with a sponge). Apply standard quantity of solution to give a thin film of coating substance on each plate. Distribute 50 µl per plate For, distribute 100 µl in pre-separator Immerse each plate in a crystalizer containing the coating material. Allow 0.5 hr for solvent evaporation in a fume hood before assembly of impactor Dip plates in solution and allow hexane to evaporate prior to assembly of impactor Inox Glycerine Coat with a thin layer of glycerine

9 ACI 10 ACI 11 ACI Liquid systems pmdi, Method 1: Brij 35 (2% w/v) in glycerol Method 2: Span-85 (1% w/v) in hexane 1% soln. Tween20 in methanol. The pre-separator is not coated Non-coated or Brij 35/ethanol 12 ACI Apiezon spray (Dekati Ltd) 13 ACI, 14 ACI, 15 ACI,, pmdi 1% w/v silicone oil in hexane 1% Tween in EtOH alternatively 1% span 85/hexane 3 g Brij 35 P dissolved in 20 ml ethanol, 1 ml of the Brij solution mixed with 5 g glycerol; alternatively: 1 % silicone oil in hexane; alternatively: 15-20 % Tween80 in glycerol; Dissolve 2.5 g Brij in 25 ml ethanol. Add 4-ml to 20 g glycerol and mix well. Apply 50 µl as coating and spread to coat entire plate surface Apply coating via a pipette, allowing excess to run of plate. Allow solvent to evaporate. Recovery of active by immersion of plate in sample diluent, gently swirling for 10-min Immerse plates, remove and air dry Pipette coating solution onto plate, wipe-off excess and allow to air dry Apply spray to plates once a day (max 6 collections) Dip plates in solution, allowing hexane to evaporate prior to assembly of impactor Dip plates in solution, allow to air dry in clean conditions. Check for homogeneous coating visually before use Distribute 50 µl solution per plate. Distribute 100 µl in pre-separator (ACI) for testing

16 ACI,, MMI pmdi/ VHC ACI; metal cups and MMI 17 ACI Aluminium or stainless A check is made for particle bounce at IQ for new impactors or formulations. Coat with a solution of Brij 35, glycerol and ethanol Releasil-B silicone spray (Dow Corning) Apply standard amount of coating material (thin) and evenly. Spray directly on to plate Conclusions The table demonstrates the wide variety of methods that are in current use by members to coat the collection surfaces of cascade impactors for the particle size assessment of a variety of inhaler types. The decision whether or not to coat the collection surfaces of the cascade impactor will depend on both the formulation and type of impactor, and should always be considered as part of the method development process [5]. References 1. USP 26-NF 21. 2003. Chapter 601 Physical tests and determinations: Aerosols. United States Pharmacopeia, Rockville, MD, USA. 2105-2123. 2. European Pharmacopeia. 2002. Section 2.9.18 Preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopeia: 3 rd Edn., Suppl. 2001. Council of Europe, 67075 Strasbourg, France. 113-124. 3. Nasr, M.M., D.L. Ross and N.C. Miller. 1997. Effect of drug load and plate coating on the particle size distribution of a commercial albuterol metered dose inhaler (MDI) determined using the Andersen and Marple-Miller impactors. Pharm. Res. 14(10):1437-1443. 4. Kamiya, A., Sakagami, M., Hindle, M. and Byron, P.R. 2003. Particle sizing with the next generation impactor: A study of Vanceril metered dose inhaler. J. Aerosol Med., 16(2): 216. 5. Christopher D., Curry, P., Doub, B., Furnkranz, K., Lavery, M., Lin, K., Lyapustina, S., Mitchell, J., Rogers, B., Strickland, H., Tougas, T., Tsong, Y. and Wyka, B. 2003. Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree. J. Aerosol Med. 16:235-247. member organizations are: 3M, Astra Zeneca, Aventis, Bespak, Boehringer Ingelheim, Chiesi, Clinical Designs, GlaxoSmithKline, Hovione, Innovata Biomed, Ivax Pharmaceticals, Novartis, Novo Nordisk, Pharmachenie, Pfizer, SkyePharma, Sofotec, Trudell Medical International and Vectura

Drug Delivery to the Lungs 14, The Aerosol Society, London, UK, 2003:75-78 PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP () J.P. Mitchell on behalf of members of the European Pharmaceutical Aerosol Group members evaluate many different aerosols from both pressurized metered dose inhalers (pmdis) and dry powder inhalers (s) by the use of a cascade impactor. It is widely recognized that pre-coating of particle collection surfaces is a prerequisite in testing to avoid bias caused by particle bounce. A summary of a recent survey is presented, in which members were asked to provide information about their impactor type and coating methodology, including the composition of the coating material applied to the collection surfaces. There is no standard approach in terms of either materials used or method of applying the coating. However, standardization is unnecessary, since each organization has independently selected and validated their procedure with their own formulations. The newcomer can therefore select from a variety of methods to eliminate particle bounce, and at the same time ensure quantitative recovery and assay of the active pharmaceutical ingredient(s).